TAS-116 (Pimitespib), an HSP90 Inhibitor, Exhibits Efficacy in Preclinical Models of Adult T Cell Leukemia

The authors investigated the anti-adult T cell leukemia/lymphoma effects of a novel oral HSP90 inhibitor TAS-116 and the mechanisms involved in ex vivo and in vivo preclinical models.